Niche matters : The comparison between bone marrow stem cells and endometrial stem cells and stromal fibroblasts reveal distinct migration and cytokine profiles in response to inflammatory stimulus by Khatun, Masuma et al.
RESEARCH ARTICLE
Niche matters: The comparison between
bone marrow stem cells and endometrial
stem cells and stromal fibroblasts reveal
distinct migration and cytokine profiles in
response to inflammatory stimulus
Masuma Khatun1, Anna Sorjamaa1, Marika Kangasniemi1, Meeri Sutinen2, Tuula Salo2,
Annikki Liakka3, Petri Lehenkari4, Juha S. Tapanainen1,5, Olli Vuolteenaho6, Joseph
C. Chen7, Siri Lehtonen1, Terhi T. Piltonen1*
1 Department of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center, University
of Oulu and Oulu University Hospital, Oulu, Finland, 2 Cancer and Translational Medicine Research Unit,
Medical Research Center, University of Oulu and Oulu University Hospital, Oulu, Finland, 3 Department of
Pathology, Medical Research Center, University of Oulu and Oulu University Hospital, Oulu, Finland,
4 Department of Anatomy and Department of Internal Medicine, Medical Research Center, University of Oulu
and Oulu University Hospital, Oulu, Finland, 5 Department of Obstetrics and Gynecology, University of
Helsinki and Helsinki University Central Hospital, Helsinki, Finland, 6 Research Unit of Biomedicine,
University of Oulu, Oulu, Finland, 7 Department of Obstetrics, Gynecology and Reproductive Sciences,
University of California, San Francisco, United States of America
* terhi.piltonen@oulu.fi
Abstract
Objective
Intrinsic inflammatory characteristics play a pivotal role in stem cell recruitment and homing
through migration where the subsequent change in niche has been shown to alter these
characteristics. The bone marrow mesenchymal stem cells (bmMSCs) have been demon-
strated to migrate to the endometrium contributing to the stem cell reservoir and regenera-
tion of endometrial tissue. Thus, the aim of the present study was to compare the
inflammation-driven migration and cytokine secretion profile of human bmMSCs to endome-
trial mesenchymal stem cells (eMSCs) and endometrial fibroblasts (eSFs).
Materials and methods
The bmMSCs were isolated from bone marrow aspirates through culturing, whereas
eMSCs and eSFs were FACS-isolated. All cell types were tested for their surface marker,
proliferation profiles and migration properties towards serum and inflammatory attractants.
The cytokine/chemokine secretion profile of 35 targets was analysed in each cell type at
basal level along with lipopolysaccharide (LPS)-induced state.
Results
Both stem cell types, bmMSCs and eMSCs, presented with similar stem cell surface marker
profiles as well as possessed high proliferation and migration potential compared to eSFs.
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In multiplex assays, the secretion of 16 cytokine targets was detected and LPS stimulation
expanded the cytokine secretion pattern by triggering the secretion of several targets. The
bmMSCs exhibited higher cytokine secretion of vascular endothelial growth factor (VEGF)-
A, stromal cell-derived factor-1 alpha (SDF)-1α, interleukin-1 receptor antagonist (IL-1RA),
IL-6, interferon-gamma inducible protein (IP)-10, monocyte chemoattractant protein (MCP)-
1, macrophage inflammatory protein (MIP)1α and RANTES compared to eMSCs and/or
eSFs after stimulation with LPS. The basal IL-8 secretion was higher in both endometrial
cell types compared to bmMSCs.
Conclusion
Our results highlight that similar to bmMSCs, the eMSCs possess high migration activity
while the differentiation process towards stromal fibroblasts seemed to result in loss of stem
cell surface markers, minimal migration activity and a subtler cytokine profile likely contribut-
ing to normal endometrial function.
Introduction
The human endometrium has a unique ability to regenerate rapidly, increasing its thickness
from 2–4 mm in the early proliferative phase to 10–15 mm by the end of the secretory phase
[1,2]. The growth of the endometrial tissue is under steroid hormone (estradiol [E2] and pro-
gesterone [P4]) control, where the monthly cycles of growth, differentiation and shedding
occur in response to ovarian hormonal fluctuations [3]. With blastocyst implantation, the
endometrium is challenged with immune tolerance, the regulation of trophoblast invasion and
vasculature formation, in which a balanced hormonal and immune environment, the niche is
crucial for successful and healthy pregnancy [4–6]. In a non-conception cycle, the endome-
trium goes through a complex inflammatory process involving cell drift and immune cell
migration leading to the activation of degradative enzymes and apoptosis, subsequent tissue
breakdowns and menstruation. Simultaneously, the molecular processes ensuring tissue regen-
eration, revascularization and histoarchitectural development are initiated, most likely through
inflammatory triggers related to menstruation-induced hypoxia, to prepare the endometrium
for the next menstrual cycle [7].
Endometrial mesenchymal stem cells (eMSCs) have been reported to reside in the peri-
vascular space in the human endometrium, most likely contributing to the monthly regen-
eration and repair of this tissue [1,3,8]. These very rare adult stem cells are defined by their
functional properties, such as substantial self-renewal, high proliferative potential and the
ability to differentiate into one or more cell lineages, including osteocytes, adipocytes and
chondrocytes [1,8]. The global gene profile analysis has revealed that eMSCs and endome-
trial stromal fibroblasts (eSFs) have similar genomic signatures, suggesting that eMSCs are
progenitors of eSFs, the most common cell type in the endometrium [2,9]. The mesenchy-
mal stem cells of different tissues have been described as having migration activity towards
the site of injury in response to secreted cytokines and chemokines [10,11]. In terms of
endometrium repair, several studies have suggested that eMSCs have a bone marrow origin:
signals related to tissue damage (menstruation) initiate bone marrow mesenchymal stem
cells’ (bmMSCs) migration to the endometrium, where they differentiate into eMSCs,
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contributing to the endometrial stem cell reservoir and thereby endometrial regeneration
[12–14].
In the human endometrium, cytokine/chemokine secretion is regulated by hormonal
fluctuations, which is one of the key factors orchestrating implantation and monthly endo-
metrial regeneration [15,16]. Steroid hormone withdrawal during the late secretory phase
leads to hypoxia, the initiation of several inflammatory processes including leucocyte recruit-
ment and increased synthesis of cytokines like interleukin 1β (IL-1β), and other inflamma-
tory modulators within the cells most likely providing the key event for homing the
bmMSCs in the endometrium [15,17,18]. Interestingly, previous studies have suggested that
mechanisms for the initiation and regulation of bmMSCs’ migration to different tissues
involve the secretion of distinct sets or even individual cytokines [19–24]. In the human
endometrium, IL-1β, a major pro-inflammatory cytokine regulating many of the endome-
trial functions, may be considered as a potential trigger for bmMSCs’ recruitment due to its
expression response to hypoxia [25–28]. On the other hand, the endometrial stem cells have
also been shown to possess migratory abilities [29,30]. However, to date, comparative studies
assessing the migratory characteristics of bmMSCs in response to inflammatory triggers
compared to the assumable endometrial progeny, eMSCs and further down in the line the
eSFs, are scarce.
Traditionally, MSCs are thought to regulate the immune response and exhibit niche-depen-
dent pro- and anti-inflammatory properties via cytokine and chemokine secretion [31]. As the
bmMSCs serve as a source for stem cells for several tissues, it is acquired that upon cell migra-
tion and change in niche, also the cytokine secretion profile and thereby paracrine signalling is
changed. Thus, the new cytokine profile may also have an effect on migration signalling of this
tissue [22]. Indeed, previous studies have assessed the cytokine secretion patterns between
MSCs of different tissues [31], however, the endometrium as a relatively new source for MSCs
remains poorly characterized, especially regarding the comparative data between bmMSCs
and different endometrial cell populations. Furthermore, it is well recognized that the basal
cytokine patterns do not correlate with the total secretion potential of the cells [32–34]. In fact,
the majority of the previous studies describe only the basal cytokine secretion profiles but not
the profiles under stimulation.
Given the plausible role of bmMSCs in endometrial regeneration through migration and
the differences in bone marrow and endometrial niche the first aim was to investigate the sur-
face marker signature and IL-1β triggered migration of bmMSCs and compare these charac-
teristics to their assumed endometrial progeny, the eMSCs and eSFs. Secondly, we also
compared for the first time the basal and stimulated cytokine secretion profiles of bmMSCs,
eMSCs and eSFs in the same study setting in order to reveal their paracrine properties that
may relate to endometrial regeneration and migration signalling but also to normal endome-
trial function. Our results show that indeed there is a specific surface marker as well as inflam-
mation driven migration profile for the bmMSCs, eMSCs and eSFs enabling more detailed
characterization of these three cell types. Moreover, the results suggest a niche effect on the
cytokine secretion characteristics that was shown as distinct cytokine secretion pattern in
bmMSCs compared with endometrial eMSCs and eSFs.
Materials and methods
Study subjects
Bone marrow aspirates (n = 12) were obtained from fertile-aged women undergoing surgery
for scoliosis in the Department of Paediatric Surgery, Oulu University Hospital, Finland. The
endometrial tissue biopsy samples (n = 15, whole uterus n = 4) were obtained from fertile-aged
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women undergoing surgery for benign gynaecological conditions, or from healthy volunteers
in the Department of Obstetrics and Gynaecology, Oulu University Hospital, Finland. One full
thickness endometrial sample from endometriosis was used in co-localization in immunofluo-
rescence and was not used in any other experiments. Clinical data on the study participants is
shown in Table 1. Informed written consent was obtained from all participants in accordance
with the guidelines of the Declaration of Helsinki, and the Ethics Committee of Oulu Univer-
sity Hospital approved the study.
Table 1. Clinical characteristics of the study subjects.
ID Obtained cell Age (years) BMI Histology Diagnosis Sample Collection Hormonal Medication Smoking
Endo 1 a, b eMSC, eSF 42 19.6 PE Myoma Pipelle No No
Endo 2 a, b eMSC, eSF 39 22.3 SE Polysuscipion Pipelle No No
Endo 3 a, b eMSC, eSF 40 26.3 PE Myoma, Menorrhagia Pipelle No No
Endo 4 a, b eMSC, eSF 23 23.1 SE Hypertophic Labia Pipelle No Yes
Endo 5 b eMSC, eSF 44 33.5 SE Myoma Pipelle No No
Endo 6 b, c, e eMSC, eSF 41 19.3 PE Left ovarian Cyst Pipelle No No
Endo 7 b, c, e eMSC, eSF 44 24.4 SE Endometrial Polyp Pipelle No No
Endo 8 b, c, e eMSC, eSF 22 18.8 SE Left ovarian Cyst Pipelle No Yes
Endo 9 c eMSC, eSF 40 26.1 SE Left ovarian Cyst Pipelle No No
Endo 10 c eMSC, eSF 37 24.6 PE Myoma Pipelle No Yes
Endo 11 b eMSC, eSF 44 36.1 N/A Pelvic floor prolapse Pipelle No No
Endo 12 b, e eMSC, eSF 41 25.6 PE Volunteer Pipelle No No
Endo 13 b eMSC, eSF 34 24.9 PE Volunteer Pipelle No No
Endo 14 b eMSC, eSF 42 38.4 PE Volunteer Pipelle No No
Endo 15 d N/A 42 27.2 SE Menorrhagia Uterus No Yes
Endo 16 d N/A 40 24.2 DQ Myoma, Menorrhagia Uterus No Yes
Endo 17 d N/A 43 30.1 PE Menorrhagia Uterus No No
Endo 18 d N/A 39 24 PE Endometriosis Uterus No No
Endo 19 e eMSC 36 20.5 SE Cysta dermoidea ovarii Pipelle No No
BM 1 a, b, c bmMSC 36 N/A N/A Scoliosis BMA N/A N/A
BM 2 a, b, c bmMSC 34 N/A N/A Scoliosis BMA N/A N/A
BM 3 a, b, c bmMSC 26 N/A N/A Scoliosis BMA N/A N/A
BM 4 a, b, c bmMSC 37 N/A N/A Scoliosis BMA N/A N/A
BM 5 a, b, c bmMSC 44 N/A N/A Scoliosis BMA N/A N/A
BM 6 a, b, c bmMSC 46 N/A N/A Scoliosis BMA N/A N/A
BM 7 a, b, c bmMSC 36 N/A N/A Scoliosis BMA N/A N/A
BM 8 a, b, c bmMSC 45 N/A N/A Scoliosis BMA N/A N/A
BM 9 e bmMSC 16 N/A N/A Scoliosis BMA N/A N/A
BM 10 e bmMSC 16 N/A N/A Scoliosis BMA N/A N/A
BM 11 e bmMSC 16 N/A N/A Scoliosis BMA N/A N/A
BM 12 e bmMSC 16 N/A N/A Scoliosis BMA N/A N/A
eMSC, endometrial mesenchymal stem cell; eSF, endometrial stromal fibroblast; bmMSC, bone marrow mesenchymal stem cell
PE, proliferative phase; SE, secretory phase; DQ, desquamation; BMA, bone marrow aspirate; N/A, Not Acquired
a Sample used in surface marker analysis
b Sample used in differentiation studies
c Sample used in migration and assays
d Sample used in immunofluorescence
e Sample used in Luminex Multiplex assay
https://doi.org/10.1371/journal.pone.0175986.t001
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Tissue processing and the Fluorescence-Activated Cell Sorting (FACS)
of endometrial cell populations
Endometrial samples were divided into two groups and processed separately for FACS and for
histological examination, as described earlier [35]. Briefly, for FACS the tissues were digested
with collagenase type I (Sigma) at 6.4 mg/ml and hyaluronidase (Sigma) at 125 U/ml and fil-
tered with a 40 μm cell strainer to separate single cells. Contaminating red cells were lysed with
0.155 M of NH4Cl, 0.1 M of KHCO3 and 0.1 mM EDTA, at a pH of 7.3 (Sigma), and the disso-
ciated cellular elements were treated with DNase (Mediq) at 4 mg/ml.
For FACS isolation, single-cell fragments of endometrial samples (n = 15) were blocked
and labelled with the following fluorochrome-conjugated antibodies (BD Biosciences) in phos-
phate-buffered saline (PBS) containing 10% human serum and 1% BSA for an hour: cluster of
differentiation (CD) 45 (phycoerythrin-Cy7 anti-CD45) at a 1:20 dilution to remove contami-
nating leucocytes; epithelial cell adhesion molecule (EPCAM; allophycocyanin anti EPCAM)
at a 1:20 dilution) to label contaminating endometrial epithelial cells, cluster of differentiation
146 (CD146, melanoma cell adhesion molecule [MCAM], fluorescein isothiocyanate anti-
MCAM) at a 1:5 dilution to label perivascular cells; β-type platelet-derived growth factor
receptor (PDGFRβ; phycoerythrin anti-PDGFRβ) at a 1:5 dilution to label eSFs (PDGFRβ+/
CD146-). Endometrial MSCs were sorted using double labelling with PDGFRβ and CD146
antibodies, both at 1:5 dilutions. DAPI staining was used for distinguishing live/dead cells
(NucBlue1, Life Technologies). The FACS-isolation protocol has previously been shown to
produce pure cell populations [2,36].
Cell culturing and the isolation of bmMSC populations
FACS-isolated eMSCs and eSFs were plated with a density of 1000–2000 cells in 10-cm plate
for eMSCs and with 200,000 cells in 10-cm plate for eSFs. Similarly to previous study, no epi-
thelial cell contamination were found in the eMSC or eSF cultures after careful monitoring
during the entire culture period [9,37]. eMSCs were cultured in phenol red-free high-glucose
DMEM growth medium (Life Technologies) supplemented with 25% MCDB-105 (Sigma),
0.676 mM of sodium pyruvate (Sigma), 10% charcoal-stripped foetal bovine serum (FBS; Sera-
lab, UK), 1% penicillin-streptomycin mix (Life Technologies) and 50 μg/ml of gentamycin
(Life Technologies). In addition, 25 μg/ml of basic fibroblast growth factor (FGFb; Life Tech-
nologies) was added to eMSC primary cultures. Growth media (without FGFb) was used in the
culturing of the eSF with 5 μg/ml of insulin (Sigma). Growth media was changed every 2–3
days and the confluency of eMSCs was maintained below 80% during culturing. The eMSCs
and eSFs were cultured up to passage two.
For the bmMSC culture, a bone marrow aspirate was plated in alpha modified essential
growth medium (Sigma) supplemented with 20 mM of Hepes, 2 mM of L-glutamine (Sigma),
10% heat-inactivated FBS (Bioclear), 10,000 U penicillin/ml and 10 mg/ml of streptomycin
(Sigma). After two days, unattached cells were removed. Half of the growth media was changed
twice per week. The confluency of bmMSCs was maintained below 80% [38]. For the final
analysis and experiments, all the cultured cells were washed with PBS and adherent cells were
detached using trypsin-EDTA solution (Gibco).
Co-localization of eMSC with markers for PDGFRβ+/ CD146+
Endometrial tissue sections obtained from hysterectomies (n = 4) were embedded in a Tissue-
Tek Optimal Cutting Temperature (OCT) compound (Miles Laboratories), frozen in liquid
nitrogen and stored at -80˚C. Perpendicular tissue samples containing both endometrium and
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myometrium were taken from the posterior uterine wall. Histological evaluation was per-
formed by a pathologist.
Frozen sections (~6μm) were fixed in methanol (-20˚C) for 10 min and permeabilized for
10 min using 0.5% Tween20 in 0.01 M of PBS (Sigma) rinse solution. The sections were
blocked in antibody dilution buffer (two parts 0.01 M of PBS, 2% BSA and 0.5% Tween20, and
one part glycerol; (Sigma)) containing 10% normal goat serum (Vector laboratories) for 1h at
room temperature (RT). Sections were washed with PBS/Tween and incubated with anti-
CD146 (Abcam, 5 μg/ml) for 1 h at RT and then overnight at +4˚C. After washing, the sections
were incubated with Alexa fluor 488 goat anti-mouse antibodies (Molecular Probes, 8 μg/ml)
for 4 h and washed in rinsing solution. The sections were then incubated for 1 h at RT and
then overnight at +4˚C with anti-PDGFRβ (Abcam, 5μg/ml). After washing, the sections were
incubated with Alexa fluor 594 goat anti-rabbit antibody (Molecular Probes, 8 μg/ml) for 4 h
at +4˚C and washed in rinsing solution at RT. The sections were then mounted in a Vecta-
shield antifade mounting medium containing DAPI (Vector, H-1200). Images were captured
using an AxioCam MRm microscope fitted with high-resolution Imager.D2 software (Carl
Zeiss).
Stem cell surface marker analysis using flow cytometry
Selected cell surface markers were identified by flow cytometry (FACS Calibur). Cultured
eMSCs, eSFs and bmMSCs (n = 4/cell type) were incubated for 20 min at RT with the follow-
ing antibodies at a dilution of 1:50: CD105, CD73, CD90, human leucocyte antigen (HLA)
ABC, CD44, CD49d, CD49f, HLA-DR1, CD34, CD45, CD14, CD19, c-MET, PDGFRβ/
CD140b or CD146 (CD90 from The Cell Technologies, all others from BD Biosciences).
Unbound antibodies were washed off and the cells were analysed using flow cytometry. Stain
intensities were recorded as follows: -, negative; +,<35%. ++, 35–70%; +++, 95–100%, indicat-
ing the proportion of cells staining positively.
Proliferation/migration assessment of cultured cells using scratch
assays
Proliferation/migration potential was analysed using a cell culture scratch assay protocol.
bmMSCs, eMSCs and eSFs (n = 4) were seeded into 24-well plates (100,000 cells/ well). Imme-
diately after reaching confluency on day 3, crisscross scratches were made with p10 pipette tips
and the medium was replaced with a culture medium containing 2% FBS. The scratched area
was monitored and photographed regularly using an EVOS Digital Inverted Microscope
(Advanced Microscopy Group, Bothell, WA, USA), starting immediately after the scratching
and ending when one of the cell types showed 100% repair of the scratched area. The empty
areas were measured using ImageJ software (version 1.50), and the results were calculated as a
percentage of the area closed by the cell growth.
Transwell® migration assays
To study vertical cell migration, Corning Transwell1 8.0 μm polycarbonate membrane 6.5
mm inserts (24-well plate, Costar 3422, Sigma) were used. bmMSCs, eMSCs or eSFs (n = 4/cell
type) were seeded (20,000 cells/well) into the upper chamber in 2% FBS culture medium in
duplicate in several repetitions. In addition, 10% FBS culture medium or 2% FBS medium
with IL-1β (Sigma) at 10 ng/ml were added to the lower chamber as attractants; 2% FBS culture
medium in both the upper and lower chamber was used as the baseline. After 24, 48, 72 and 96
h of migration, the inserts were fixed with 4% paraformaldehyde and stained with 1% toluidine
blue + 1% sodium tetraborate. Non-migrating cells from the top of the membrane were
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removed using a cotton swab. The dye attached to the migrated cells was eluted by dipping the
inserts into 1% sodium dodecyl sulphate (Roche), followed by measuring the absorbance at
650 nm using a Wallac Victor 2™ Multilabel counter.
Lipopolysaccharide (LPS) stimulation and Luminex multiplex assays
For the cytokine secretion analysis, eMSCs, eSFs and bmMSCs (n = 4/cell type) were plated to
24-well plates with a seeding density of 20,000–50,000 cells/well. After reaching 80% con-
fluency, the cells were switched to growth media containing 2% FBS. After 48 h, the cells were
challenged with 10 ng/ml of LPS supplemented in 2% FBS growth media, keeping control cells
in 2% FBS growth media. After 24 h of LPS treatment, the cell culture media was collected and
the cells were harvested from the wells with trypsin-EDTA solution (Gibco).
Cytokines, chemokines and related proteins like Eotaxin, granulocyte macrophage colony
stimulating factor (GM-CSF), melanoma growth stimulatory activity alpha (GRO-α), interferon
alpha 1 (FNA1), interferon gamma (FNG), interleukin (IL)-10, IL-12p70, IL-13, IL-15, IL-17A,
IL-18, IL-1a, IL-1β, IL-1RA, IL-2, IL-21, IL-22, IL-23, IL-27, IL-31, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-9, interferon-gamma inducible protein-10 (IP-10), monocyte chemoattractant protein
(MCP-1), macrophage inflammatory protein 1-alpha (MIP-1α), macrophage inflammatory
protein 1-beta (MIP-1β), regulated on activation, normal T-cell expressed and secreted
(RANTES), stromal cell-derived factor 1 alpha (SDF-1α), tumour necrosis factor-alpha (TNF-
α), tumour necrosis factor-beta (TNF-β) and vascular endothelial growth factor VEGF-A) were
quantified with eBioscience ProcartaPlex Human Cytokine & Chemokine 34plex supplemented
with VEGF-A Simplex kit using a Luminex MagPix system and Luminex xPonent Software.
The culture medium samples were assayed both undiluted and after a 1:10 dilution. Milliplex
Analyst software (VigeneTech) was used for the multiplex assay data extraction. The coefficient
of determination (R2) of the 5-parameter logistic regression standard curves were between
0.999 and 1.000 in all assays, and the standard curve CVs were between 0.15% (MIP-1β) and
2.7% (IL-27). Total protein was isolated from the cells using Tri Reagent for RNA, DNA and
protein isolation (Sigma), and the results were normalized (using a dilution factor) against total
protein measured with a Direct Detect1 Infrared Spectrometer (Merck Millipore).
Statistical analysis
The results are presented as the mean ± SD. Analysis of variance between groups was per-
formed with one-way ANOVA, using a nonparametric approach when appropriate. T-tests
and nonparametric Mann-Whitney, when appropriate, were carried out as post-hoc tests. P-
values< 0.05 were considered statistically significant. IBM SPSS statistics software version
22.0 and Graphpad prism 6 was used for all statistical analyses.
Ethical approval
The sample collection was approved by the ethics committee of Oulu University Hospital
(PPSHP) under the statement number 22/2013 at 18/02/2013. The data did not include any
identification information from the patients and was handled only by the members of the
research team.
Results
FACS isolation and co-localization of (PDGFRβ+/CD146+) markers
In FACS analysis, epithelial cells (epithelial cell adhesion molecule (EPCAM+)), leucocytes
(CD45+) and endothelial cells (β-type platelet-derived growth factor receptor (PDGFRβ-)
BmMSCs’ migration and cytokine profile compared with endometrial cells
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/CD146+)) were gated out (Fig 1A and 1B), and eMSCs and eSFs were isolated according to
their staining patterns (eSFs, PDGFRβ+/CD146-; eMSCs, PDGFRβ+/CD146+; Fig 1C). The
eMSCs clustered separately from the eSFs, indicating the purity of downstream cell culture
populations. In immunofluorescence, eMSCs were located in the perivascular space in the
basal layer (Fig 1D–1G), as well as in the functional layer (data not shown).
BmMSCs and eMSCs present with similar stem cell surface marker
profiles
Both bmMSCs and eMSCs presented with a typical stem cell surface antigen profile showing
positive staining for CD105, CD90, CD73, CD44, CD49d and CD49f. All cell types were nega-
tive for haematopoietic cell markers CD45, CD34, CD19, CD14, human lymphocyte antigen-
DR (HLA-DR), the carcinoma cell marker (c-MET) and EPCAM (Fig 2D). The surface marker
analysis of passage 2 cultured cells revealed that eMSCs were still strongly positive for PDGFRβ
and CD146, whereas bmMSCs and eSFs were positive only for PDGFRβ (Fig 2A–2C).
BmMSCs and eMSCs demonstrate high proliferation potential and a
robust migration response to inflammatory attractant
In the scratch assay protocol, the closing of the scratched area was measured until one of the
cell types showed 100% closing of the scratch (Fig 3A). From 27 h onwards, eMSCs and
bmMSCs showed similar proliferation/migration capacities (85–88%), both presenting closing
of the scratch at 45 h. Interestingly, the eMSCs had the highest proliferation/migration rate
compared with bmMSCs and eSFs at the early time points (22 h: 72% vs. 57% and 50%,
P<0.05) (Fig 3B). The eSFs had a significantly lower proliferation/migration capacity than
eMSCs and bmMSCs at all time points, but showed a confluence of up to 90% at 45 h (Fig 3B).
Fig 1. FACS sorting of eMSCs, eSFs and localization of eMSCs in the human endometrium. (A) Endometrial cell populations were isolated
from a single live cell fraction using DAPI stain. (B) Contaminating epithelial cells (EP) (Epcam+) and leucocytes (CD45+) were gated out. (C) eSFs
positive for β-type platelet-derived growth factor receptor (PDGFRβ) and negative for cluster of differentiation 146 (CD146, melanoma cell adhesion
molecule [MCAM]) and eMSCs (PDGFRβ+/CD146+) were isolated (areas Q1 and Q2). (D-G) eMSCs were identified in the perivascular space in the
basal layer of proliferative phase human endometrium by identifying co-localization of CD146 (green) and PDGFRβ (red) expression (white arrows).
Scale bar 5 μm.
https://doi.org/10.1371/journal.pone.0175986.g001
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After assessing the optimal vertical migration time period, the end point was set to 96 h for
all cell types (Fig 4). The cell migration from 2% towards 10% serum attractant revealed the
high migration potential of bmMSCs compared with endometrial cells up to 48 h (p< 0.05).
However, eMSCs showed the highest migration activity at 96 h while no significant migration
was observed among eSFs (Fig 4A). When the cells were subjected to cytokine chemoattraction
with IL- 1β, the migration activity of bmMSCs and eMSCs increased up to 72 h. The eMSCs
demonstrated the highest migration activity at 72 h with IL- 1β trigger (+125% compared with
bmMSCs, +200% compared with eSFs), whereas the eSFs did not show any significant migra-
tion (Fig 4B).
Fig 2. Surface marker analysis of bmMSCs, eMSCs and eSFs. (A, C) bmMSCs and eSFs were positive only for PDGFRβ and negative for
CD146. bmMSCs were also strongly positive for CD105 and CD44, whereas eSFs were negative for CD105 and showed only low expression of
CD44. (B) eMSCs presented with double staining for PDGFRβ and CD146 and were strongly positive for CD105 and CD44. (D) A summary table of
surface marker analysis.
https://doi.org/10.1371/journal.pone.0175986.g002
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LPS-stimulated eMSCs and eSFs possess a quiescent cytokine/
chemokine secretion pattern compared with bmMSCs
From the original 35 analytes, the following 16 analytes were detected in the Luminex analysis
in a basal and/or LPS-stimulated state: VEGF-A, SDF-1α, IL-1RA, IL-6, IP-10, MCP-1, MIP-
1α, RANTES, IL-8, MIP-1β, GRO-α, GM-CSF, IL-1α, IL-2, IL-31 and Eotaxin. The expression
of all targets is presented in Table 2. In general, the cytokine secretion pattern of bmMSCs was
pronounced compared with the endometrial cell types, and only a few differences were shown
between eMSCs and eSFs. bmMSCs showed eminently higher levels of VEGF-A, SDF-1α, IL-
1RA, IL-6, IP-10, MCP-1, MIP-1α and RANTES than eMSCs and/or eSFs with most of the dif-
ferences being shown after LPS stimulation (p<0.05, Fig 5A, Table 2). The VEGF-A and SDF-
1α secretion in bmMSCs was high at both basal levels as well as after LPS stimulation com-
pared with eMSCs and eSFs. The basal IL-8 secretion was significantly higher in the endome-
trial cell populations than bmMSCs, and after LPS stimulation the secretion tended to be still
lower in bmMSCs compared with endometrial cells types (p<0.05, Fig 5B, Table 2). MIP-1β,
and GRO-α were similarly expressed before and after LPS stimulation in all three cell types
(Fig 5B, Table 2). Interestingly, the eMSCs and eSFs showed overall a relatively low cytokine
secretion pattern compared with bmMSCs, and there were only a few differences between
eMSCs and eSFs showing higher expression of IL-1RA, IP-10 and RANTES in eSFs compared
to eMSCs. Several cytokines undetected at the basal state, however, presented with high
Fig 3. Migration/proliferation capacity of bmMSCs, eMSCs and eSFs in scratch assays at 0, 27 and 45 h. (A) Demonstration of one
of the eMSCs samples at 0 h (left), 27 h (middle), and 45 h time points (right). All eMSCs reached 100% closure of the scratch by 45 h.
Pictures captured at 10x magnification; scale bar 50 μm. (B) Quantitative data of closed scratch areas over time in bmMSCs, eMSCs and
eSFs showing higher proliferation/migration potential in eMSCs and bmMSCs compared with eSFs. Statistical analysis: *bmMSCs vs.
eSFs, †eMSCs vs. eSFs, §bmMSCs vs. eMSCs; p<0.05.
https://doi.org/10.1371/journal.pone.0175986.g003
BmMSCs’ migration and cytokine profile compared with endometrial cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0175986 April 18, 2017 10 / 21
(IL1-RA and IP-10) or moderate response (GM-CSF, IL-1α, IL-2, IL-31 and Eotaxin) after LPS
stimulation (Fig 5A and 5B, Table 2).
Discussion
This is the first study to compare the surface marker characteristics, migration potential and
cytokine profiles between bmMSCs, eMSCs and eSFs in the same study setting. The results
reveal that both bone marrow and endometrial stem cells share similar surface markers along
with the high proliferation activity and migration potential compared to eSFs implying that
differentiation process towards eSF-phenotype alters these characteristics. Interestingly, the
bmMSCs show distinct differences in their cytokine secretion profiles whereas the endometrial
cells have more similar profile plausibly due to sharing the similar niche compared with
bmMSCs (Fig 6).
Fig 4. Vertical migration assays of bmMSCs, eMSCs and eSFs followed up till 96 h. (A) Using serum
attractant (2% serum in upper and 10% in lower chamber), the eMSCs seemed to accelerate migration
activity compared to other cell types up till 96 h (B) Inflammatory attraction was assessed by using IL-1β (10
ng/ml) in the lower chamber. The migration response was high in both stem cell population whereas no
significant migration activity was observed in eSFs. § p<0.05 bmMSCs vs. eMSCs; * p<0.05 bmMSCs vs.
eSFs; † p<0.05 eMSCs vs. eSFs.
https://doi.org/10.1371/journal.pone.0175986.g004
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According to the previous studies, the bmMSCs serve as progenitors for endometrial
eMSCs [12,39]. On the other hand, recently, the link between eMSCs and eSFs was strengthen,
as these two cell types revealed similar gene expression profiles and in vitro, the eMSCs were
shown to differentiate into eSFs [2,9]. In keeping with this, the present data showed the
Table 2. Cytokine secretion analysis of bmMSCs, eMSCs and eSFs with Luminex multiplex assay.
Target Detection limit (pg/ml) Basal secretion (pg/ml ± STDEV) LPS stimulated secretion (pg/ml ± STDEV) p-value
bmMSCs eMSCs eSFs bmMSCs eMSCs eSFs
IL-1α 0.45 UDL UDL UDL 3.6 ± 2.2 4.2 ± 4.8 2.8 ± 0.6
IL-1β 0.59 ND ND ND ND ND ND
IL-1RA 25.46 UDL UDL UDL 6372 ± 7060 71.1 ± 84.6 1017 ± 1260 *, #
IL-2 4.47 UDL UDL UDL 15.5 ± 2.5 10.5 ± 2.4 10.6 ± 2
IL-4 10.99 ND ND ND ND ND ND
IL-5 8.8 ND ND ND ND ND ND
IL-6 9.2 771 ± 1090 215 ± 140 310 ± 200 23939 ± 22420 4342 ± 1730 3862 ± 1320 *, ^
IL-7 0.26 ND ND ND ND ND ND
IL-8 (CXCL8) 2.01 7.4 ± 5.8 168 ± 110 220 ± 180 7837± 7120 21090 ± 10160 24900 ± 13900 $, "
IL-9 7.46 ND ND ND ND ND ND
IL-10 1.57 ND ND ND ND ND ND
IL-12p70 3.23 ND ND ND ND ND ND
IL-13 1.0 ND ND ND ND ND ND
IL-15 0.8 ND ND ND ND ND ND
IL-17A 1.87 ND ND ND ND ND ND
IL-18 12.6 ND ND ND ND ND ND
IL-21 6.93 ND ND ND ND ND ND
IL-22 6.94 ND ND ND ND ND ND
IL-23 14.81 ND ND ND ND ND ND
IL-27 18.67 ND ND ND ND ND ND
IL-31 6.3 UDL UDL UDL 10.8 ± 2.4 9.5 ± 3.5 12.8 ± 8.4
TNF-α 7.02 ND ND ND ND ND ND
TNF-β 5.6 ND ND ND ND ND ND
IFN-α 0.51 ND ND ND ND ND ND
IFN-γ 10.82 ND ND ND ND ND ND
GM-CSF 5.57 UDL UDL UDL 13.0 ± 5.7 16.4 ± 7.9 17.1 ± 8.2
MCP-1 (CCL2) 1.02 231 ± 310 5.0 ± 4.6 64.5 ± 67.3 8606 ± 8540 66.5 ± 67.7 551 ± 440 *, ^, $
MIP-1α (CCL3) 0.54 4.6 ± 5 UDL 2.2 ± 2 25.7 ± 8.8 3.5 ± 3.3 9.9 ± 4.9 *, ^
MIP-1β (CCL4) 1.56 49.4 ± 47 10.3 ± 3.5 31.2 ± 24.8 576 ± 320 217 ± 160 406 ± 130
RANTES 0.54 3.3 ± 3.3 0.6 ± 0.03 2.7 ± 1.5 106 ± 150 5.6 ± 3.2 22.3 ± 17.5 *, #
EOTAXIN (CCL11) 0.6 UDL UDL UDL 4.3 ± 1.6 1.8 ± 0.6 2.7 ± 0.6 *
GRO-α (CXCL1) 2.57 8.5 ± 7.9 3.3 ± 0.9 6.7 ± 5.1 642 ± 460 456 ± 480 619 ± 290
IP-10 (CXCL10) 0.9 UDL UDL 2.0 ± 1.3 544 ± 740 6.0 ± 5.8 60.4 ± 71 *, #
SDF-1α (CXCL12) 10.15 383 ± 290 87.1 ± 48.6 175 ± 120 1634 ± 450 298 ± 200 738 ± 330 *, ^
VEGF-A 3.3 870 ± 430 5.0 ± 2.7 43.6 ± 50.9 1438 ± 830 101 ± 85.5 257 ± 120 *, ^, $, "
ND = not detected, UDL = under detection limit
* p<0.05 bmMSCs vs.eMCs after LPS stimulation
^ p<0.05 bmMSCs vs.eSFs after LPS stimulation
# p<0.05 eMSCs vs.eSFs after LPS stimulation
$ p<0.05 bmMSCs vs.eMCs in basal state
”p<0.05 bmMSCs vs.eSFs in basal state
https://doi.org/10.1371/journal.pone.0175986.t002
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bmMSCs and eMSCs presenting with similar, well-known stem cell surface marker character-
istics and eMSCs with high clonogenic potential compared with eSFs [1,40,41]. Furthermore,
supporting the idea that the eMSCs are more likely to be of bmMSCs origin rather than direct
progeny of the haematopoietic stem cell lineage, all three cell types were negative for haemato-
poietic cell surface antigens [42].
In accordance with the data showing stem cells being involved in different repair processes,
the bmMSCs and eMSCs were found to have higher proliferation potential than differentiated
Fig 5. Basal and LPS-stimulated cytokine secretion analysis of bmMSCs, eMSCs and eSFs with Luminex multiplex assay. The overall
cytokine pattern was shown to be pronounced in bmMSCs compared to endometrial cell types. (A) Cytokines highly expressed by bmMSCs vs.
eMSCs and eSFs. (B) Cytokines having equal or higher expression in eMSCs and eSFs compared with bmMSCs. UDL = under detection limit; *
p<0.05 bmMSCs vs. eMSCs or eSFs; # p<0.05 eMSCs vs. eSFs. Basal level (black), LPS stimulated (gray).
https://doi.org/10.1371/journal.pone.0175986.g005
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eSFs. Furthermore, the stem cells also showed high migration activity, an important ability
enabling homing into the site of injury in regenerative processes. Even though the endometrial
stem cells are not known to have any specific role as migratory cells, the data is in line with pre-
vious study validating also high migration potential in adipose tissue driven MSCs compared
to bmMSCs [43]. Furthermore, the data underline the notion that also harboured stems cells
retained the migration potential that may be activated with certain triggers as also suggested to
be the case for human endometrial stem cells [44]. On the other hand, the eSFs did not present
with significant migration potential indicating that differentiation process towards eSF-pheno-
type alters the migration capacity and thus limit the number of migratory cells in human endo-
metrium. In fact, similar to the findings by Barragan et al., in the present study the eMSCs also
started rapidly differentiating in vitro into eSFs shown as loss of CD146 expression [9]. At Pas-
sage 2, only 70% of the eMSCs expressed CD146, indicating an active differentiation process
towards eSFs even though the cells were cultured only for a relatively short time and they were
not allowed to reach 100% confluence. Whether this feature relates to decreased migration
activity in eMSCs cannot be concluded from the present data, however, one may hypothesize
that in case of impaired differentiation process towards eSFs, as shown by Barragan et al., the
retained migration ability of eMSCs might be of relevance regarding pathologies like endome-
triosis and adenomyosis.
The collapse of the endometrium during menstruation leads to hypoxia and a vast inflam-
matory cascade that most likely serve as recruitment signals for stem cells to harbour
Fig 6. Schematic depiction of bmMSC migration to human endometrium in response to hormonal/cytokine driven homing signals. (A) The
migration of bmMSCs to the human endometrium contributes to the endometrial stem cell pool (the endometrial mesenchymal stem cells, eMSCs) and
thereby endometrial renewal. The change in niche and the differentiation process towards eSFs will alter the migration properties and the cytokine
secretion profile of these cells. (B-C) The estrogen (E2) and progesterone (P4) effect and their withdrawal will drive endometrial collapse and
subsequent hypoxia during the late secretory phase of the menstrual cycle most likely triggering the homing signal for the bmMSCs for the subsequent
cycle.
https://doi.org/10.1371/journal.pone.0175986.g006
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endometrium [28,45–47]. IL-1 is a potent cytokine with several functions, including a role in
immune balance during the implantation process along with the regulatory role in menstrua-
tion by modulating inflammatory cascades. Ex utero studies have also shown that the bmMSCs
are being recruited by specific growth factors/cytokines, one of them being IL-1β [48]. Given
that IL-1β is abundant during menstruation and its expression is strongly linked to hypoxia, it
may play as one of the endometrium-related recruiting signals for bmMSCs [26–28]. In the
present data IL-1β was able to trigger high migration response both in bmMSCs and eMSCs,
with eMSCs presenting even higher migration response to IL-1β than the bmMSCs. Whether
this is of clinical importance in maintaining eMSCs in the endometrium is not clear but poten-
tially high peripheral IL-1β could recruit eMSCs to ectopic locations. Moreover, recently endo-
metrial stromal cell SDF-1 expression was shown to be involved in bmMSC recruitment where
estrogen promoted the expression of SDF-1 receptor CXCR4 [46]. Given that IL-1β has been
shown to promote SDF-1 expression [49], it may be that these signals together with hormonal
regulation play a role driving bmMSC recruitment and harbouring to the human
endometrium.
The change in niche upon stem cell migration and its effect on intrinsic inflammatory char-
acteristics may also give insight into the differences between bmMSCS, eMSCs and eSFs. To
date, only few studies have been done regarding the comparison between bmMSCs’ cytokine
secretion profile to eMSCs’ or eMSC cytokine profile compared to other endometrial cell types
[37,50,51] and no data exist on PDGFRβ+/CD146+ isolated eMSCs. Furthermore, most of the
studies have only investigated the basal cytokine secretion profile, although it is well estab-
lished that it is not sufficient to characterize the full secretion potential of these cells [30,32,33].
Indeed, in the present data, the major differences in cytokine secretion profiles between the
different cell types were shown under LPS-induced inflammation. The LPS response in the
cells might occur through toll-like receptor 4 (TLR4) activation shown recently in mesenchy-
mal stem cells [52] but also in rodent and human endometrium [53,54]. The bmMSCs exhib-
ited a robust cytokine expression of several targets (VEGF-A, SDF-1α, IL-1RA, IL-6, IP-10,
MCP-1, MIP-1α and RANTES) in response to LPS stimulation compared with endometrial
cell types. IL-1β, on the other hand, was not detected in either eMSC or eSF secretome, thus
implying immune cells most likely being the major source for this particular cytokine during
endometrial shedding [37]. The secretion of VEGF-A, a growth factor necessary for endome-
trium vasculature repair related to hypoxia [55–59], was demonstrated in all three cell types;
however, the bmMSCs presented with higher expression than endometrial cells. This is in line
with the important role of bmMSCs in regeneration processes in general [48]. Interestingly,
the VEGF-A secretion pattern was not in line with the previous data by Gaafar et al. showing
higher VEGF-A expression in endometrial cells than bmMSCs [60]. The reason for this dis-
crepancy might be due to the fact that the eMSCs in the Gafaar´s work were obtained through
culturing and not by FACS isolation, thus possibly including also other cells than mesenchy-
mal stem cells. On the other hand, in line with previous studies, the bmMSCs were shown to
produce high levels of SDF-1α [46], whereas the secretion was moderate from the endometrial
cells. The SDF-1/CXCR4 signalling is considered crucial for bmMSC recruitment in general,
and, as mentioned earlier, recently the endometrial stromal cell SDF-1α was also shown to
attract mouse bmMSC through CXCR4 activity promoted by estrogen [46,61]. As for both
VEGF-A and SDF-1 secretion profile it might be that in order to avoid abundant endometrial
bmMSC migration and balanced bmMSC recruitment, the endometrium presents with more
quiescent secretion profile for these pivotal signals.
IL-8 has been found to have an important role regulating the recruitment of leucocytes to
the endometrium and promoting endometrial stromal viability and proliferation [62,63]. The
LPS-stimulated IL-8 levels were comparable in all three cell types; however, interestingly, the
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basal IL-8 levels were slightly elevated in endometrial cells compared with the bmMSCs. Fur-
thermore, some of the cytokine targets that have been demonstrated to play a role in implanta-
tion processes and correlate with the implantation success in IVF treatments were expressed
evenly by bmMSCs and both endometrial cell types (MIP-1β, GRO-α) or even more robustly
by bmMSCs (MCP-1, IP-10) [64,65]. These data are of importance, especially considering a
recent study where bmMSCs therapy was carried out successfully for patients with thin endo-
metrium leading to the endometrial repair and live birth [13]. As expected, a subset of cyto-
kines was not detected at the basal level, but their secretion was triggered by the inflammatory
stimuli extending the cytokine profile of these cells (IL-1RA, IP-10, GM-CSF, IL-1α, IL-2, IL-
31 and Eotaxin). From these specifically ILR1A, IP-10, GM-CSF and EOTAXIN are all shown
to be involved in implantation process controlling trophoblast cell attraction/invasion [66–
70]. Altogether, one can speculate that the subtle cytokine expression pattern of the endome-
trial cell types compared with the bmMSCs might serve normal endometrial function by facili-
tating a balanced endometrial niche and by providing a non-hostile environment for the
implanting embryo.
The strength of the study lies in the rigorously collected rare human sample depository with
paired endometrial samples. Although obtaining bmMSCs and endometrial cell population
from the same patient would result into even more rigorous data, in practice this was not feasi-
ble. As MSCs have been shown to lose some of their properties with ageing [71,72], only sam-
ples from reproductive-aged women were included. Regarding the endometrial cell types,
Schwab et al. demonstrated that FACS sorting of the eMSCs with PDGFRβ+/ CD146+ double
staining yielded cells with a more stem cell-like phenotype compared to magnetic sorted
eMSCs [1]. Thus, in our study, the purity of endometrial cell types was enhanced by FACS iso-
lation with PDGFRβ/CD146-labeling. There are also several limitations that need to be
addressed. Due to the small sample size, the study is considered as a pilot in vitro study that
lays ground for future experiments regarding the investigations on endometrial renewal and
endometrium-related pathologies like endometriosis and adenomyosis. Moreover, the hor-
monal and paracrine secretion or the interaction of other endometrial cells types on the meta-
bolic/immunuosecretory properties of MSC populations was not assessed. As for the
migration assay, the effects of other cytokines/chemokines and growth factors or the synergis-
tic effects of other endometrial cell types cannot be concluded.
Conclusions
This is the first study including bmMSCs, eMSCs and their progeny eSFs in the same study set-
ting, allowing the simultaneous and more precise comparison of these three cell types regard-
ing their proliferative, migratory and inflammatory characteristics. The data showed similar
surface marker profiles and high migration potential towards inflammatory attractants in
bmMSCs and eMSCs, while the endometrial cell population sharing similar niche had distinct,
subtler, cytokine profile compared with bmMSCs. While bmMSCs’ high proliferation and
migration potential supports their role in different renewal processes, including human endo-
metrium, one can hypothesize, that the change in the cytokine secretion profile along differen-
tiation process towards eSFs might enable a subtler cytokine profile possibly contributing to
normal endometrial function.
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